Debiopharm and Ubix Therapeutics Launch Research to Develop a New Anti-Cancer Modality - Antibody Degraducer® Conjugates

The two companies are aiming to develop a new drug modality known as Antibody DegraducerConjugates (ADeC), by combining one of Ubix's Degraducer molecule, with Debiopharm's antibody drug conjugate linker Multilink.